Recent Updates
Recently added Catalysts
WVE

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

Wednesday, June 2, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency.
ShareAdd on Google
Tags: WVE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 2, 2021

Biotech snapshot

Cash runway
$491M liquidity · $18M/mo burn
~27 mo
Minimal dilution risk
Lead asset
WVE-N531Phase 2
Duchenne Muscular Dystrophy →

Catalyst track record

+13%
best trade around WVE's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for WVE.

See every catalyst's timing & PoA →